Polymyositis, dermatomyositis, and necrotizing myopathy are diseases that are often treated with immunoglobulin (Ig) products, either intravenously (IV) or subcutaneously (SC). Many TMA members find IVIg or SCIg to be a very effective treatment. Recently, however, TMA has become aware of shortages of Ig products in some areas of the country. IVIg and SCIg are…
Continue Reading
TMA executive director Mary McGowan, TMA member and patient advisor Darlene Shelton, and pulmonologist Dr. Cheilonda Johnson were interviewed for an informative article by Ty Fenwick in the Indianapolis Recorder, an African American weekly newspaper in Indiana. The article, “Don’t confuse it with old age: Myositis diseases can be deadly,” highlights the disparity of risk…
Continue Reading
The following article about living with myositis appeared in the Orlando Sentinel on Friday, May 17, 2019. See the original article here. By Miyoshi Gordon-Matthews In 1995, I was playing basketball in the driveway with my then 9-year old son when I fell. I did not think much of it. Until the next day, when…
Continue Reading
TMA celebrates National Occupational Therapy Month (April) with a conversation with Dr. Malin Regardt, an occupational therapist on our Medical Advisory Board. “As occupational therapists, we talk to patients about the kinds of activities they have problems with, so we can help them develop new strategies,” Malin says. While patients might list many things that…
Continue Reading
Recent study findings from TMA research fellow Dr. Simon Rothwell will soon be published in the medical journal Annals of Rheumatic Diseases. This work is related to myositis autoantibodies and unique genetic differences that we previously did not know about. This is a summary of the soon-to-be published results of this study.
Continue Reading